Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China

AbbVie

Status: Completed

Conditions: Non-Segmental Vitiligo

Study type: Observational

Funder types: Industry

Identifiers

NCT07058051

H25-976

Details and patient eligibility

About

The purpose of this study is to evaluate the patterns of treatment, healthcare resources utilized and the burdens associated with non-segmental vitiligo (NSV) amongst participants in China

This study is a cross-sectional, multicenter, observational study of vitiligo patients in China. The cross-sectional design is sufficient to characterize the overall current burden of NSV.

Full description

Cross-Sectional

Enrollment: 100 patients

Sex: All

Ages: 12 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female patients, age ≥ 12.
• Chinese patients meet the diagnosis of Non-Segmental Vitiligo (NSV) and 5≤ Total Vitiligo Area Scoring Index (T-VASI<50) with or without facial involvement.
• Medical history available within the last 6 months.
• Ability to understand the questionnaires, with parental support as required for adolescents (between ≥ 12 and < 18 years of age at inclusion visit).
• Willing to provide a patient authorization form to use and disclose personal health information (or informed consent, where applicable) to participate in the study; for adolescent subjects, authorization and/or consent will be provided by a parent or legal guardian, where applicable.

Exclusion criteria

• Unable or unwilling to comply with study requirements and electronic Patient-Reported Outcome (ePRO) collection.
• Segmental or localized vitiligo.
• Greater than 33% leukotrichia in areas of vitiligo on the face or on the body.
• History of active skin disease other than vitiligo that could interfere with the assessment of vitiligo.
• Patients who are participating in interventional clinical trial(s) at time of study visit.
• Patients who are currently receiving treatment with any investigational drug/device/intervention or have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) prior to enrollment.